<DOC>
	<DOCNO>NCT02455960</DOCNO>
	<brief_summary>This trial perform examine efficacy oral L-arginine prevent CI-AKI chronic kidney disease ( CKD ) patient .</brief_summary>
	<brief_title>Protective Effects Oral L-Arginine CI-AKI</brief_title>
	<detailed_description>Contrast-induced acute kidney injury ( CI-AKI ) common complication hospitalize patient . Nitric oxide-signal transduction play important role prevention CI-AKI . L-Arginine amino acid involve ammonia detoxification , well know precursor nitric oxide , key component endothelial-derived relaxing factor . This prospective randomized , double blind , placebo control trial among CKD stage 3-4 patient undergo computer tomography . Eligible patient randomly assign two group : ( 1 ) arginine 3 g/day 6 capsule per day , ( 2 ) placebo 6 capsule per day 3 day contrast medium injection . Serum cystatin C , serum creatinine estimate GFR measure baseline 48 hour procedure .</detailed_description>
	<criteria>Age â‰¥ 18 year Stable CKD stage 34 patient Patients undergoing elective contrast medium injection History arginine allergy Acute kidney injury diagnose within 4 week Active infection/sepsis Severe liver disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>